Question-and-Answer SessionWith that, we begin the Altimmune fireside chat, and we are excited to have you here. So for those who do not know the story of Altimmune, can you give us a brief background of yourselves and a brief background of the company at a higher level and what you're currently focused on?Vipin GargPresident, CEO & Director Absolutely. Well, thank you for having us. We appreciate it. I'm Vipin Garg, President and CEO of Altimmune; and my colleague, Dr. Scott Harris, our Chief Medical Offic ...

公司背景 - 公司专注于开发GLP-1胰高血糖素双受体激动剂pemvidutide 用于治疗严重肝脏疾病如MASH [1] - 药物设计兼具肝脏直接作用与代谢益处 通过胰高血糖素直接作用于肝脏 GLP-1成分主要通过减重提供代谢效益 [1][2] 药物机制 - pemvidutide通过胰高血糖素成分实现肝脏直接作用 通过GLP-1成分实现减重等代谢效益 [1][2] - 治疗MASH的最佳方式需同时针对肝脏直接作用和全身代谢改善 [2] 研发重点 - 当前研发聚焦于严重肝脏疾病领域 特别是MASH治疗 [1] - 公司管理层包括首席执行官和首席医疗官共同推进临床开发 [1]